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The difference of burden of ectopic 
beats in different types of atrial 
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prospective cohort of patients with 
atrial fibrillation (CODE-AF registry)
Seunghoon cho1,11, Jun Kim2,11, Jin-Bae Kim3, Junbeom park4, Jin-Kyu park5, Ki-Woon Kang6, 
Jaemin Shim7, Eue-Keun choi8, Young Soo Lee9, Hyung Wook park10,12* & Boyoung Joung1,12*
The relationship between atrial fibrillation (AF) type and stroke risk is still controversial. We 
investigated the difference of burden of atrial ectopic beats in different types of AF and the effect of the 
AF type on stroke risk in patients with non-valvular AF. In the prospective, multicenter observational 
registry with more than about 10,000 AF patients, 8883 non-valvular AF patients (mean age, 67.0 years; 
36% were women) with eligible follow-up visits participated. We compared the burden of ectopic beats 
and stroke risk between patients with paroxysmal AF (n = 5,808) and non-paroxysmal AF (n = 3,075). 
The patients with a non-paroxysmal type of AF were older, male-predominant and had a higher 
prevalence of comorbidities and had more anticoagulation and rhythm control treatment than those 
with paroxysmal AF. In terms of the difference in burden of ectopic beats, patients with non-paroxysmal 
AF had a higher proportion of atrial premature beats (APBs) (paroxysmal vs. non-paroxysmal, median 
3% vs. 5%; p = 0.001) in 24 hours Holter monitoring. During a median follow-up period of 16.8 months 
(Interquartile range [IQR], 11.67–20.52), a total of 82 (0.92%) patients experienced ischemic stroke 
with incidence rates of 0.50 and 1.09 events per 100 person-year for paroxysmal and non-paroxysmal 
AF, respectively. The cumulative incidence of stroke events was significantly higher in non-paroxysmal 
AF than in paroxysmal AF (p < 0.001). The risk of ischemic stroke was higher in non-paroxysmal AF 
with an adjusted hazard ratio (HR) of 2.08 (95% confidence interval [CI], 1.33–3.25; p = 0.001) than in 
paroxysmal AF. The type of AF was associated with an increased risk of stroke, along with the difference 
of burden of ectopic beats (specially in APBs) in different types of AF. These results suggest that the 
type of AF should be considered in stroke prevention and decision-making for oral anticoagulation in AF 
patients.
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Atrial fibrillation (AF) is the most common cardiac arrhythmia, and it affects ~1–2% of the general population; its 
prevalence is also increasing constantly with the increasing aging population1–4. AF is associated with increased 
risk of mortality and many adverse outcomes such as stroke, thromboembolism, heart failure5. AF is also related 
to a five-fold increase in stroke risk, and one in five cases of stroke is attributed to AF6–8. With the increasing epi-
demiological burden, AF is becoming an increasingly important factor in stroke occurrence2,3,6–8.
To date, several studies have reported that patients with paroxysmal AF have a risk of stroke events similar 
to that in patients with persistent and permanent AF9–12. Based on the results of previous studies, the current 
guidelines do not include the type of AF as a risk stratification factor13,14. Similarly, the Korean guidelines do 
not include the type of AF as a risk factor. However, the association between the type of AF and stroke risk still 
remains controversial15. Several studies have shown that patients with paroxysmal AF have a lower incidence 
rate of stroke than those with non-paroxysmal forms of AF, although they are less likely to receive oral anticoag-
ulant (OAC) therapy in actual clinical practice12,16,17. In addition to several studies dealing with the relationship 
between AF type and stroke risk, some studies on the relationship between implantable cardiac device-detected 
AF burden and thromboembolic risk, including stroke, have revealed that AF burden is associated with elevated 
risk for stroke and thromboembolism18–20. On the other hand, there have been several works on the associa-
tion between the burden or frequency of atrial ectopic beats and recurrent stroke, transient ischemic attack, and 
death21–24. Results from EMBRACE Trial and several studies also have revealed that excessive APBs is associated 
with the development of atrial fibrillation and adverse cardiovascular events25–27.
This study was performed to investigate the effect of the AF type on stroke risk in patients with non-valvular 
AF and to investigate the difference of burden of ectopic beats in different types of AF.
Materials and Methods
Study design and methods. The COmparison study of Drugs for symptom control and complication 
prEvention of Atrial Fibrillation (CODE-AF) was a prospective, multicenter, observational study performed in 
patients with AF aged >18 years attending any of the 18 tertiary centers encompassing all geographical regions of 
Korea. The study enrollment period started in June 2016 and ended in May 2019.
The aim of the CODE-AF registry is to describe the clinical epidemiology of patients with AF and to deter-
mine the diagnostic and therapeutic processes (including organization of programs for AF management) applied 
to these patients and their clinical outcomes17.
Data collection was usually conducted by personnel with no clinical activity assigned to the project17,28. 
The Congestive heart failure/left ventricular dysfunction, Hypertension, Age of 75 years (doubled), Diabetes, 
Stroke (doubled), Vascular disease, 65–74 years of Age, and Sex category (female) (CHA2DS2-VASc) score and 
Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, 
Drugs/alcohol concomitantly (HAS-BLED) score were calculated for all patients with non-valvular AF17,28. 
Follow-up was scheduled at every 6 months, either via personal interview or telephone contact (data not 
shown)17,28.
The registry was funded by the National Evidence-Based Healthcare Collaborating Agency and designed and 
coordinated by the Korea Heart Rhythm Society, which provides support to related committees, national coordi-
nators, and participating centers. Data are entered into a common electronic database that limits inconsistencies 
and errors and provides online help for key variables. Each center can see its own data and data from all other 
participating centers17,28. The study was approved by the ethics committee of each center, and all patients pro-
vided informed consent for their inclusion. The study was conducted in compliance with the ethical rules of the 
Declaration of Helsinki as a statement of ethical principles for medical research involving human subjects by The 
World Medical Association. We followed the ethical, scientific and medical standards that protect the rights of 
participants and we required informed consent from all study participants, and the review and approval of study 
protocols, including patient information forms, by ethics committees.
This study was registered at ClinicalTrials.gov (NCT02786095). The Ethics Committees of all 18 tertiary 
centers include followings; Severance Hospital, Seoul National University Hospital, Korea University Medical 
Center, Daegu Catholic University Medical Center, Ewha Womans University Medical Center, Daejeon Eulji 
University Hospital, Kyung Hee University Hospital, Hanyang University Seoul Hospital, Chonnam National 
University Hospital, Asan Medical Center, Inha University Hospital, Gangnam Severance Hospital, Samsung 
Medical Center, CHA Bundang Medical Center, Seoul St. Mary’s Hospital, Seoul National University Bundang 
Hospital, Keimyung University Dongsan Medical Center, Dong-a University Hospital.
A total of 10,663 patients older than 18 years with non-valvular AF were enrolled in the CODE-AF regis-
try from June 2016 to May 2019. Patients with uncategorized types of AF (n = 106) and those without eligible 
follow-up periods (at least 6 months, n = 1,644) were excluded. Finally, 8,883 patients were enrolled in this study; 
the enrolled patients were categorized into two groups according to their type of AF as follows: paroxysmal AF 
(n = 5,808), non-paroxysmal AF (n = 3,075) (Fig. 1).
Definition and classification of AF type. The current classification of the AF type is based on the clinical 
presentation and the duration and frequency of AF episodes detected by electrocardiogram (ECG) recordings at 
variable duration and intensity of monitoring5. Based on the clinical presentations of AF and taking into account 
the available data on arrhythmia duration, we classified and defined the type of AF as follows independently of 
their symptoms5,13.
• Paroxysmal AF, which is a self-terminating form of arrhythmia lasting less than 7 days;
• Persistent AF, which is a form of AF lasting longer than 7 days or requiring termination by cardioversion 
(pharmacological or electrical cardioversion) for sinus rhythm restoration;
• Permanent AF, which is a form of AF for which cardioversion is not attempted, as the arrhythmia is accepted 
by the patient and physicians
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The patients were classified into three groups (three clinical subtypes of AF at the time of enrollment) based 
on their diagnosis, baseline ECG recordings, and clinical history. When comparing the stroke risks among the 
three groups, the total patient number was relatively very small in permanent AF (paroxysmal n = 5808, persis-
tent n = 2806, permanent n = 269) and the baseline characteristics in permanent AF were similar to persistent AF 
(Supplementary Table 1). Furthermore, most of the distinction between persistent AF and permanent AF were 
decided subjectively by clinicians. for this reason, we combined these 2 subtypes as non-paroxysmal AF in this 
study to facilitate the comparative analysis according to AF type and compared baseline clinical characteristics 
and outcomes between paroxysmal AF and non-paroxysmal AF.
Continuous monitoring of cardiac rhythm by a Holter monitor made it possible to obtain data on the presence 
and duration of arrhythmias and its distribution. The burden of ectopic beats referred to this study included the 
percentage of atrial premature beats (APBs) and ventricular premature beats (VPBs) assessed via a Holter mon-
itoring. We analyzed these parameters obtained by a Holter monitoring as indicators that can reflect the burden 
of ectopic beats.
Study endpoint. The primary endpoint of this study was the occurrence of stroke events during the 
follow-up period. The other clinical endpoints included systemic thromboembolism (STE), all-cause death, and 
composite endpoints that contained stroke, STE, all-cause death during the follow-up period. Patients who expe-
rienced >1 stroke recurrence during the follow-up period were censored at the time of the first event. Stroke 
was defined as the sudden onset of a focal neurological deficit in a location consistent with the territory of the 
major cerebral artery, and the diagnosis of ischemic stroke was confirmed by computed tomography or magnetic 
resonance imaging12. STE was defined as an acute vascular occlusion of an extremity or major organ with related 
symptoms confirmed by imaging modalities such as computed tomography or ultrasonography12.
Statistical analysis. Continuous variables were presented as mean ± standard deviations (SD) for normal 
distribution value or median [interquartile range (IQR)] for non-normal distribution value and categorical var-
iables as numbers and percentages in each group. The baseline characteristics of the two groups were compared 
using student’s T-test or Mann Whitney U-test for continuous variables and Pearson’s χ2 test or Fisher’s exact 
test for categorical variables. The Kaplan–Meier method was used to estimate the cumulative incidence of stroke 
events and other clinical events. Differences in the cumulative incidence curves between the two groups were 
evaluated using the log-rank test. We used Cox regression model for multivariate analysis to assess the inde-
pendent relationship between the AF type and stroke events, other clinical events adjusting for clinical variables, 
including age, sex, hypertension, diabetes, dyslipidemia, prior stroke/transient ischemic attack, congestive heart 
failure, prior myocardial infarction or peripheral arterial occlusive disease and anticoagulant, antiplatelet, statin 
use. Cox regression analysis was also used to confirm the statistical significance between burden of ectopic beats 
and stroke risk. Associations were presented as hazard ratios (HR) with 95% confidence intervals (CI). Statistical 
analyses were performed using the R statistical software (version 3.6.1). All reported p-values were based on 
two-sided tests, and p-values of <0.05 were considered statistically significant.
Results
Baseline characteristics. The mean age of the study population was 67 ± 11 years. Male sex was more 
predominant (n = 5,689, 64.0%). The median CHA2DS2-VASc score and HAS-BLED score were 3 (IQR, 1–4) and 
2 (IQR, 1–2) points, respectively. The median follow-up period of the enrolled patients was 16.8 months (IQR, 
11.67–20.52).
The comparison of the baseline characteristics between the two study groups is presented in Table 1. The 
patients with non-paroxysmal AF were older, male-predominant and had a higher prevalence of comorbidities 
Figure 1. Flow diagram of the study participants. n refers to the number of patients. AF, atrial fibrillation; IQR, 
interquartile range.
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such as hypertension, diabetes, history of stroke and transient ischemic attack, and valvular heart disease and 
congestive heart failure and also had higher CHA2DS2-VASc score and larger left atrium size (all p < 0.05) than 
the patients with paroxysmal AF. Patients in the non-paroxysmal AF group were also more frequently treated 
with OAC therapy and rhythm control medications than those in the paroxysmal AF group. On the other hand, 
patients with paroxysmal AF were more prescribed with aspirin and had more history of catheter ablation.
Differences of burden of ectopic beats in different types of AF. A total of 4,861 patients without per-
manent AF underwent a Holter monitoring. The burden of ectopic beats was obtained through a Holter monitor 





AF (n = 3075) p-value
Age in years 66.55 ± 11.03 68.00 ± 10.73 <0.001
Female sex (%) 2160 (37.2) 1034 (33.6) 0.001
Body mass index (kg/m2) 24.51 ± 3.28 24.94 ± 3.46 <0.001
Systolic BP (mmHg) 122.43 ± 15.10 122.59 ± 15.76 0.637
Diastolic BP (mmHg) 74.66 ± 11.44 75.64 ± 12.21 <0.001
Heart rate (/min) 74.18 ± 16.54 79.61 ± 16.89 <0.001
Hypertension (%) 3804 (65.6) 2124 (69.2) 0.001
Diabetes (%) 1399 (24.1) 839 (27.4) 0.001
Dyslipidemia (%) 2148 (37.0) 996 (32.6) <0.001
History of stroke/TIA (%) 837 (14.4) 509 (16.6) 0.008
History of myocardial infarction (%) 182 (3.1) 77 (2.5) 0.108
Valvular heart disease (%) 409 (7.1) 419 (13.7) <0.001
Congestive heart failure (%) 411 (7.1) 470 (15.3) <0.001
Chronic kidney disease (%) 576 (9.9) 300 (9.8) 0.84
End-stage renal disease (%) 101 (1.8) 40 (1.3) 0.132
Peripheral arterial occlusive disease (%) 320 (5.5) 178 (5.8) 0.622
Cancer (%) 528 (9.1) 358 (11.6) <0.001
CHA2DS2-VASc score 2 [1–4] 3 [2–4] <0.001
HAS-BLED score 2 [1–2] 2 [1–2] 0.182
NT-proBNP (ng/mL) 0.44 [0.13–1.72] 0.93 [0.34–2.59] <0.001
Troponin T (ng/mL) 0.01 [0.01–0.02] 0.01 [0.01–0.02] 0.002
LA size (mm) 41.0 [37.0–46.8] 46.0 [42.0–51.4] <0.001
LAVI (mL/m2) 37.1 [28.3–51.9] 50.0 [38.8–64.0] <0.001
LV ejection fraction (%) 63.0 [58.0–68.0] 60.0 [55.0–65.0] <0.001
E/E’ 10.1 [8.0–13.3] 11.0 [8.4–14.2] <0.001
Implantable cardiac device (%) 420 (7.2) 117 (3.8) <0.001
History of catheter ablation (%) 933 (16.1) 368 (12.0) <0.001
History of cardioversion (%) 672 (11.6) 690 (22.5) <0.001
Medications
Warfarin (%) 950 (16.4) 641 (20.8) <0.001
NOAC (%) 1753 (30.2) 1177 (38.3) <0.001
Aspirin (%) 1060 (18.3) 470 (15.3) <0.001
Clopidogrel (%) 377 (6.5) 196 (6.4) 0.866
Cilostazol (%) 28 (0.5) 14 (0.5) 0.99
Beta-blocker (%) 2691 (46.3) 1639 (53.3) <0.001
Calcium channel blocker (%) 1582 (27.2) 902 (29.3) 0.039
Statin (%) 1991 (34.3) 1043 (33.9) 0.75
ARB/ACEi (%) 2124 (36.6) 1413 (46.0) <0.001
Class Ic AAD (%) 2282 (39.3) 723 (23.5) <0.001
Class III AAD (%) 790 (13.6) 494 (16.1) 0.002
Digitalis (%) 313 (5.4) 292 (9.5) <0.001
Table 1. Baseline characteristics according to each type of AF. Categorical data are presented as numbers (%) 
and continuous data are presented as mean ± standard deviations for normal distribution value or median 
[interquartile range] for non-normal distribution value. AAD, anti-arrhythmic drug; ACEi, angiotensin 
converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BP, blood pressure; 
E/E’, early diastolic transmitral velocity (E) to early myocardial velocity (E’) ratio; LA, left atrium; LAVI, left 
ventricular volume index; LV, left ventricle; NOAC, non-vitamin K oral anticoagulant; NT-proBNP, N-terminal 
pro B-type natriuretic peptide; TIA, transient ischemic attack.
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burden between the two study groups and to assess the relationship between the ectopic burden and risk of clin-
ical events including stroke.
The APB burden was significantly higher in non-paroxysmal AF (median, 5%; IQR, 2–11%) than in parox-
ysmal AF (median, 3%; IQR, 2–9%). The VPBs burden in non-paroxysmal AF was similar (median, 3%; IQR, 
1.7–8.8%) to paroxysmal AF (median, 3%; IQR, 1–7%), and not statistically significant (Fig. 2).
Multivariate analysis and Other outcomes. During a median follow-up period of 16.8 months (IQR, 
11.67–20.52), a total of 82 (0.92%) patients experienced ischemic stroke with incidence rates of 0.50 and 1.09 
events per 100 person-year for paroxysmal and non-paroxysmal AF, respectively. Incidence rates of STE events 
per 100 person-year were 0.07 and 0.15 for paroxysmal and non-paroxysmal AF, respectively. In all-cause death, 
incidence rates per 100 person-year were 0.48 and 0.68 for non-paroxysmal AF and paroxysmal AF. In the com-
posite outcome, incidence rates per 100 person-year were 1.14 and 2.03 for non-paroxysmal AF and paroxysmal 
AF (Table 2). In subgroup without persistent AF, incidence and risk of stroke and other outcome were higher in 
persistent than paroxysmal AF (Supplementary Table 2).
The cumulative incidence of stroke was significantly higher in non-paroxysmal AF than in paroxysmal AF 
(p < 0.001). There was no significant difference in the cumulative incidence of STE between the two AF groups 
(p = 0.22). The cumulative incidence of all-cause death was slightly different as the follow-up period increased, 
but there was no statistical significance (p = 0.16). lastly, the cumulative incidence of composite outcomes was 
statistically higher in non-paroxysmal AF (p < 0.001) (Fig. 3).
In the Cox regression analysis, the patients with non-paroxysmal AF had a higher risk of ischemic stroke 
than the patients with paroxysmal AF during the follow-up period. The unadjusted HR was 2.19 (95% CI, 1.42–
3.39; p < 0.001). After adjustment for clinical variables, the type of AF remained an independent risk factor for 
ischemic stroke with an adjusted HR of 2.08 (95% CI, 1.33–3.25; p = 0.001). Adjusted HRs of STE and all-cause 
death were 1.35 (95% CI, 0.40–4.53; p = 0.627) and 1.24 (95% CI, 0.75–2.05; p = 0.399), respectively without sta-
tistical significance. However, the risk of the composite outcome was significantly higher in non-paroxysmal AF 
patients with an adjusted HR of 1.61 (95% CI, 1.18–2.20; p = 0.002) (Table 2).
Subgroup analysis for stroke risk. A subgroup analysis was performed to identify the association between 
the ectopic burden and stroke risk in 4,861 patients without permanent AF who underwent a Holter monitoring. 
Although the differences of APB burden measured by a Holter monitoring between two study groups were statis-
tically significant, there was no significant relationship between increased APB burden, and stroke risk and other 
clinical event risks (Table 3).
To investigate how the AF type influences stroke risk according to different subgroups, we performed sub-
group analysis of stroke risk by dividing the study patients according to several clinical variables (Fig. 4). The 
adjusted HR for stroke represented the relative risk ratio of non-paroxysmal AF to stroke incidence compared to 
paroxysmal AF during the follow-up period in each patient subgroups divided by clinical variable.
In the subgroup of low CHA2DS2-VASc scores (<2, In current guidelines, not requiring anticoagulant ther-
apy) and the subgroups with younger age (Age ≤ 65) and no anticoagulation and without hypertension, there 
was no statistical significance with the adjusted stroke risk of non-paroxysmal AF compared to paroxysmal AF. 
However, the overall adjusted HR for stroke was statistically significant, and there were no significant in-group 
differences in the effects of AF type on stroke occurrence in any subgroup, including age, sex, other comorbidities, 
and anticoagulant, antiplatelet use.
Figure 2. Differences in burden of atrial and ventricular ectopic beats according to types of AF on 24 hours 
Holter monitoring. Box plots represent the median percentage of ectopic beats (%) and interquartile range on 
a Holter monitor for each type of AF. AF, atrial fibrillation; APBs, atrial premature beats; PAF, paroxysmal AF; 
VPBs, ventricular premature beats.
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Discussion
Main findings. The main finding of the present study was that the patients with non-paroxysmal AF had a 
significantly higher risk of stroke than the patients with paroxysmal AF. Even after adjustment of confounding 
factors, the effect of AF type on stroke risk was still significant and the AF type still was an important factor in 
Endpoint
Incidence rate (per 100 person-year) HR (95% CI)




Stroke 0.50 1.09 2.19 (1.42–3.39)* 2.08 (1.33–3.25) 0.001
Other clinical endpoints
STE 0.07 0.15 1.35 (0.40–4.53) 0.627
All-cause death 0.48 0.68 1.24 (0.75–2.05) 0.399
Composite outcome (Stroke, 
STE, All-cause death) 1.14 2.03 1.61 (1.18–2.20) 0.002
Table 2. Incidence rates and adjusted HR of stroke and other clinical events according to AF type in Cox 
regression analysis. *p < 0.001 for unadjusted HR in stroke risk. **Adjusted for age, sex, hypertension, diabetes, 
dyslipidemia, prior stroke/transient ischemic attack, congestive heart failure, prior myocardial infarction/
peripheral arterial occlusive disease, and anticoagulant, antiplatelet, statin use. AF, atrial fibrillation; CI, 
confidence interval; HR, hazard ratio; STE, systemic thromboembolism.
Figure 3. Cumulative incidence curves of primary outcome and other clinical outcomes in patients with 
different types of AF. (A) Stroke, (B) STE, (C) All-cause death, (D) Composite outcome. AF, atrial fibrillation; 
PAF, paroxysmal AF; STE, systemic thromboembolism.
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stroke occurrence. The Holter monitor results of 5,013 patients revealed that the APB burden was significantly 
different depending on the AF type, especially higher in patients with non-paroxysmal AF. However, there was 
no significant direct association between increasing burden of ectopic beats and stroke risk. The reason for more 
ectopy in the non-paroxysmal AF in this study might be explained by the factor that ectopy is more common in 
patients with structural and more severe heart disorders. Actually, the non-paroxysmal AF group in this study 
had more comorbidities.
In the multivariate regression analysis of other clinical events, the results showed that the composite outcome 
had a significant HR for patients with non-paroxysmal AF. Of course, this was due to a relatively high incidence 
of stroke in the composite outcome, but the difference in mortality during the follow-up period between the two 
groups was also thought to have some effect.
In subgroup analysis, there were no significant in-group differences between subgroups in the effect of AF type 
on stroke occurrence. These results suggest that the AF type might be related to the stroke risk independently of 
Endpoint
Incidence rate (per 100 person-year) HR (95% CI)
p-value
Low APB burden 
(APB < 5%)
High APB 






Stroke 0.76 (0.16–0.22) 0.94 (0.19–2.74) 1.20 (0.23–6.08) 0.824
Other clinical endpoints
STE 0.25 (0.01–1.41) 0 — —
All-cause death 0.76 (0.16–2.21) 0.63 (0.76–2.26) 1.19 (0.18–7.72) 0.855
Composite outcome (Stroke, 
STE, All-cause death) 6.95 (3.18–13.2) 5.44 (2.0–11.9) 0.85 (0.30–2.42) 0.764
Table 3. Incidence rates and adjusted HR of stroke and other clinical events according to APB burden 
of ectopic beats in a subgroup without permanent AF. **Adjusted for age, sex, hypertension, diabetes, 
dyslipidemia, prior stroke/transient ischemic attack, congestive heart failure, prior myocardial infarction/
peripheral arterial occlusive disease, and anticoagulant, antiplatelet, statin use. AF, atrial fibrillation; APB, atrial 
premature beat; CI, confidence interval; HR, hazard ratio; STE, systemic thromboembolism.
Figure 4. A subgroup analysis representing the adjusted HR of non-paroxysmal AF compared to paroxysmal 
AF in each subgroup when grouping by each clinical variable. AF, atrial fibrillation; CI, confidence interval; HR, 
hazard ratio; OAC, oral anticoagulants; PAF, paroxysmal AF; STE, systemic thromboembolism.
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different age and different CHA2DS2-VASc score. So, it means that the type of AF should be considered in stroke 
prevention and application of OAC therapy, particularly in young AF patients with low CHA2DS2-VASc score 
who not requiring anticoagulant therapy in current guidelines.
Controversy over AF type, AF burden, and stroke risk. The stroke risk in the different types of AF 
has been controversial. Historically, the risk of ischemic stroke has been considered to be regardless of the AF 
type9,29,30. Patients with a substantial clinical risk of stroke (CHA2DS2-VASc score, ≥2) have been anticoagulated 
regardless of their AF type. In contrast, several studies showed that the risk of stroke was lower in anticoagulated 
patients with paroxysmal AF than in those with non-paroxysmal AF12,16,31.
The SOS AF project, a pooled analysis of three prospective studies with 10,016 patients who were implanted 
with electronic devices, reported that the device-detected AF burden was associated with an increased 
risk of ischemic stroke after adjusting for the CHA2DS2 score and anticoagulant use32. In the ASSERT study, 
device-detected atrial tachyarrhythmias (atrial rate, >190 bpm for >6 min) were associated with an increased 
risk of ischemic stroke or systemic embolism during a 2.5-year follow-up period33,34. In the KP-RHYTHM Study, 
a greater burden of AF identified using a noninvasive, 14-day continuous patch devices monitoring is associated 
with a higher risk of ischemic stroke and thromboembolism in adults with paroxysmal AF35. A recent study from 
Kaplan et al. has shown that the duration of AF and CHA2DS2-VASc scores are both important components in 
assessing stroke risk and therefore in determining when OAC therapy should be initiated36.
The current practice guidelines recommend a risk-stratification approach for stroke and using OAC treatment 
based on the CHA2DS2-VASc score in patients with AF13,14,29. However, deciding whether to offer anticoagulation 
to patients with a lower risk of stroke is less clear. Further, the application of OAC therapy in actual clinical prac-
tice varies depending on the patients’ age, underlying disease, bleeding risk, and life expectancy17. For patients 
with a lower risk for whom the risk-benefit ratio of anticoagulation is less clear, it could be useful to consider the 
type of AF for decision-making regarding OAC therapy5.
The relationship between the AF type or burden and the stroke risk, independently of the CHA2DS2-VASc 
score, is still unclear19. Despite the heterogeneity and uncertainty of outcomes in various studies dealing with 
the relationship between the AF type and stroke risk, considering the current guidelines and the results from 
several studies including this study, the present study suggests that the current stroke risk prediction model in 
patients with AF, in which the risk of thromboembolic events is equivalent in different types of AF, may need 
to be re-evaluated; further, the type of AF should be considered as an additional risk factor to prevent ischemic 
stroke. Further studies are needed to evaluate the impact of the integration of the AF type into thromboembolic 
risk models.
Study limitations. There are several limitations in this study. First, although the present study was a pro-
spective study that included a large patient population and had a regular patient follow-up for every six months, 
the number of clinical events including stroke was rather small and the duration of follow-up was relatively short. 
The stroke incidence in this large population of patients was only 0.92%. The relatively low stroke rate of this study 
population can be explained by several factors. Compared with recent non-vitamin K oral anticoagulant (NOAC) 
studies, this study included patients with younger age and lower stroke risk factors (Supplementary Table 3). Our 
previous study showed that OAC was used in 82.7% of patients, and NOAC in more than two-third of OAC pre-
scribed patients in this registry17. Moreover, persistence to OAC declined for 6 months only to 95.5% for NOAC37. 
Therefore, high OAC rate with high NOAC usage, and high persistent rate might be related with low stroke rate 
in this study. Second, the relationship between AF burden and stroke was not properly evaluated in this study. 
AF burden cannot be accurately assessed by a Holter monitor, due to the known daily variation in frequency38. 
Prolonged rhythm surveillance with implantable cardiac devices is necessary to assess the burden accurately19,39. 
We also could not find a statistically significant relationship between this burden of ectopic beats and stroke inci-
dence. Third, in this study, the type of AF was assessed by clinician assessment. However, continuous arrhythmia 
monitoring might improve the accuracy of the type of AF. Clinician assessment of rhythm type is an imprecise 
science, particularly in the absence of continuous arrhythmia monitoring. Prior work from Charitos et al. shows a 
lack of concordance between clinical assessment and actual rhythm status as monitored by implantable devices40. 
Fourth, in baseline characteristics, there were somewhat differences in clinical variables such as age, sex, comor-
bidities and drug use between the two study groups. Although important factors that can affect the outcome have 
been adjusted, there may still be significant confounders such as the proportion of patients appropriately treated 
with OAC and other major comorbidities which may act as another important factor. Fifth, the antithrombotic 
drugs and doses were selected at the discretion of the attending physician and there was a lack of data about drug 
use and drug compliance during the follow-up period. And lastly, we did not consider the progression of AF 
during the follow-up period after determining the type of AF at the time of enrollment. A recent study showed 
that the risk of stroke was lower in patients with maintained paroxysmal AF than in those with paroxysmal AF at 
baseline that progressed to persistent or permanent AF at the 3-year follow-up41.
Conclusion
This prospective, multicenter large-scale registry study revealed that the patients with non-paroxysmal AF had 
a significantly higher burden of ectopic beats than those with paroxysmal AF and that non-paroxysmal AF was 
associated with an increased risk of ischemic stroke compared with paroxysmal AF. In conclusion, the type of AF 
should be considered in stroke prevention and decision-making for oral anticoagulation in AF patients. Further 
investigations to understand the role of AF type in stroke risk will be needed. New treatment to prevent AF pro-
gression may be important to prevent stroke incidence and improve the survival of AF patients.
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